Tokiwa Bio
Tokiwa Bio Corporation is dedicated to developing and creating innovative gene and cell therapies using its pioneering stealth-type RNA vector (SRV) technology. Their mission is to contribute to the global fight against genetic diseases by providing safe and stable gene expression systems for regenerative medicine and gene therapy. They aim to make a significant impact in the advanced medical field by developing safe gene delivery vectors, supporting drug discovery, and advancing regenerative medicine.
Industries
Nr. of Employees
small (1-50)
Patents
Gene expression system using stealthy RNA, and gene introduction/expression vector including said RNA
US-11926840-B2
View DetailsGene expression system using stealthy RNA, and gene introduction/expression vector including said RNA
US-11834667-B2
View DetailsGene expression system using stealthy RNA, and gene introduction/expression vector including said RNA
US-10544431-B2
View Details
Gene expression system using stealthy RNA, and gene introduction/expression vector including said RNA
US-11926840-B2
View DetailsGene expression system using stealthy RNA, and gene introduction/expression vector including said RNA
US-11834667-B2
View DetailsGene expression system using stealthy RNA, and gene introduction/expression vector including said RNA
US-10544431-B2
View DetailsProducts
Stealth RNA vector product series for iPSC generation and controls
A series of research-use-only RNA vector products optimized for iPSC reprogramming from different source cells (fibroblasts, peripheral blood mononuclear cells, CD34+ cells) and a fluorescent control vector for transduction assessment. Products include performance specifications (CIU/tube, recommended MOI) and supporting SDS/protocol documents.
Stealth RNA vector product series for iPSC generation and controls
A series of research-use-only RNA vector products optimized for iPSC reprogramming from different source cells (fibroblasts, peripheral blood mononuclear cells, CD34+ cells) and a fluorescent control vector for transduction assessment. Products include performance specifications (CIU/tube, recommended MOI) and supporting SDS/protocol documents.
Services
Contract service to incorporate customer-specified genes into RNA vector backbones, produce vector material according to agreed specifications, and deliver product with supporting documentation and confidentiality protections.
Contract service to incorporate customer-specified genes into RNA vector backbones, produce vector material according to agreed specifications, and deliver product with supporting documentation and confidentiality protections.
Expertise Areas
- Gene therapy vector development
- Induced pluripotent stem cell (iPSC) generation and reprogramming
- Regenerative medicine and cell therapy enabling technologies
- Custom vector design and contract manufacturing for research/biopharma
Key Technologies
- RNA-based viral vector platforms (negative single-stranded RNA backbone)
- Self-erasable vector mechanisms (miRNA/siRNA-responsive)
- Multi-gene payload engineering
- iPSC reprogramming factor delivery
News & Updates
Announcement of the successful stable production of high-quality cat iPS cells without gene insertion, a world first.
A groundbreaking achievement in gene therapy and regenerative medicine by producing high-quality cat iPS cells without gene insertion.
Development of a unique iPSC line from a patient with Alzheimer’s disease carrying APP-V715M mutation, showing mitochondrial dysfunction.
Announcement of the successful stable production of high-quality cat iPS cells without gene insertion, a world first.
A groundbreaking achievement in gene therapy and regenerative medicine by producing high-quality cat iPS cells without gene insertion.
Development of a unique iPSC line from a patient with Alzheimer’s disease carrying APP-V715M mutation, showing mitochondrial dysfunction.